The stock of Adamis Pharmaceuticals Corporation (ADMP) has seen a -15.03% decrease in the past week, with a -61.59% drop in the past month, and a -31.91% decrease in the past quarter. The volatility ratio for the week is 9.95%, and the volatility levels for the past 30 days are at 13.57% for ADMP. The simple moving average for the last 20 days is -43.02% for ADMP stock, with a simple moving average of -58.80% for the last 200 days.
Is It Worth Investing in Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) Right Now?
while the 36-month beta value is 1.35.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The public float for ADMP is 148.38M, and currently, short sellers hold a 1.05% ratio of that floaft. The average trading volume of ADMP on March 17, 2023 was 1.28M shares.
ADMP) stock’s latest price update
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)’s stock price has decreased by -7.78 compared to its previous closing price of 0.12. however, the company has experienced a -15.03% decrease in its stock price over the last five trading days.
Analysts’ Opinion of ADMP
The stock of Adamis Pharmaceuticals Corporation (ADMP) has seen a -15.03% decrease in the past week, with a -61.59% drop in the past month, and a -31.91% decrease in the past quarter. The volatility ratio for the week is 9.95%, and the volatility levels for the past 30 days are at 13.57% for ADMP. The simple moving average for the last 20 days is -43.02% for ADMP stock, with a simple moving average of -58.80% for the last 200 days.
Analysts’ Opinion of ADMP
Many brokerage firms have already submitted their reports for ADMP stocks, with Maxim Group repeating the rating for ADMP by listing it as a “Buy.” The predicted price for ADMP in the upcoming period, according to Maxim Group is $1.50 based on the research report published on May 13th of the previous year 2020.
ADMP Trading at -46.08% from the 50-Day Moving Average
After a stumble in the market that brought ADMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.57% of loss for the given period.
Volatility was left at 13.57%, however, over the last 30 days, the volatility rate increased by 9.95%, as shares sank -62.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.44% lower at present.
During the last 5 trading sessions, ADMP fell by -15.33%, which changed the moving average for the period of 200-days by -77.11% in comparison to the 20-day moving average, which settled at $0.1862. In addition, Adamis Pharmaceuticals Corporation saw -34.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ADMP starting from Marguglio David J., who sale 11,859 shares at the price of $0.60 back on Mar 18. After this action, Marguglio David J. now owns 233,906 shares of Adamis Pharmaceuticals Corporation, valued at $7,117 using the latest closing price.
CARLO DENNIS J PHD, the President & CEO of Adamis Pharmaceuticals Corporation, sale 10,490 shares at $0.60 during a trade that took place back on Mar 18, which means that CARLO DENNIS J PHD is holding 285,867 shares at $6,287 based on the most recent closing price.
Stock Fundamentals for ADMP
Current profitability levels for the company are sitting at:
- -1451.97 for the present operating margin
- -211.14 for the gross margin
The net margin for Adamis Pharmaceuticals Corporation stands at -1566.56. Equity return is now at value -259.40, with -135.80 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 3.14.
Conclusion
In a nutshell, Adamis Pharmaceuticals Corporation (ADMP) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
